Nanotheranostics for gynecological cancers: a path forward for Africa
- PMID: 39704911
- DOI: 10.1007/s12032-024-02582-4
Nanotheranostics for gynecological cancers: a path forward for Africa
Abstract
Nanoparticle-based therapies represent a transformative approach to managing gynecological cancers, offering targeted treatment strategies that minimize harm to healthy tissues while maximizing therapeutic efficacy. Despite their potential, implementing these advanced treatments in Africa is needed by a complex interplay of technological, economic, regulatory, and ethical challenges. This paper examines the current landscape of nanoparticle-based therapies, identifying critical barriers to their adoption, including inadequate infrastructure, high costs, and insufficient regulatory frameworks. Technological deficiencies manifest as a need for advanced nanoparticle synthesis, delivery, and diagnostics equipment, impeding research and clinical applications. Economically, the high production costs of nanoparticles, compounded by limited access to advanced diagnostic and treatment facilities, create significant financial barriers for healthcare systems and patients alike. Additionally, the regulatory environment needs to be more cohesive, characterized by a lack of established protocols and expertise to evaluate the unique properties of nanomedicines. However, opportunities for advancement exist through focused research and development initiatives. Targeted drug delivery systems, early detection methods, and immunotherapy integration are promising avenues to enhance treatment outcomes. Collaborative partnerships between African institutions and international research entities, alongside public-private collaborations, could bolster local capabilities in nanomedicine. To facilitate the integration of nanoparticle-based therapies, African governments must prioritize funding for nanomedicine research, create robust regulatory frameworks, and ensure equitable access to these innovative treatments. A concerted effort involving policy reforms, investment, and collaboration is essential for overcoming existing barriers and realizing the full potential of nanoparticle-based therapies in improving health outcomes for gynecological cancer patients across Africa.
Keywords: Africa; Gynecological cancers; Nanomedicine; Nanoparticle-based therapies; Nanotheranostics; Targeted drug delivery.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Ethical approval and consent to participate: The study was approved by the ethics committee of the selected universities. Informed consent was obtained from all participating students, ensuring that their participation was voluntary and that their confidentiality was maintained throughout the study. Consent for publication: Not applicable.
Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Polymer Nanoparticles Advancements for Gynecological Cancers.Int J Nanomedicine. 2025 May 26;20:6721-6742. doi: 10.2147/IJN.S527023. eCollection 2025. Int J Nanomedicine. 2025. PMID: 40452785 Free PMC article. Review.
-
How Advanced Is Nanomedicine for Atherosclerosis?Int J Nanomedicine. 2025 Mar 17;20:3445-3470. doi: 10.2147/IJN.S508757. eCollection 2025. Int J Nanomedicine. 2025. PMID: 40125442 Free PMC article. Review.
-
Nanotheranostics, a future remedy of neurological disorders.Expert Opin Drug Deliv. 2019 Feb;16(2):113-128. doi: 10.1080/17425247.2019.1562443. Epub 2019 Jan 7. Expert Opin Drug Deliv. 2019. PMID: 30572726 Review.
-
Voyage of theranostic liposomes for imaging and therapy.J Cosmet Laser Ther. 2017 Aug;19(4):245-249. doi: 10.1080/14764172.2017.1279331. Epub 2017 Jan 31. J Cosmet Laser Ther. 2017. PMID: 28135901 Review.
References
-
- D’Augè TG, Giannini A, Bogani G, Di Dio C, Laganà AS, Di Donato V, et al. Prevention, screening, treatment and follow-up of gynecological cancers: state of art and future perspectives. Clin Exp Obstet Gynecol. 2023;50(8):160.
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. - PubMed
-
- Zoure AA, Bayala B, Bambara HA, Sawadogo AY, Ouedraogo C, Lobaccaro JMA, et al. Epidemiological situation and medical management of gynaecological and breast cancers from 1998 to 2018 in West Africa: a systematic review. Asian Pacific J Cancer Biol. 2020;5(4):211–9.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources